ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Sensitive: B - Late Trials
|
palbociclib Sensitive: B - Late Trials
|
ER mutation
|
Breast Cancer
|
ER mutation
|
Breast Cancer
|
palbociclib Resistant: B - Late Trials
|
palbociclib Resistant: B - Late Trials
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
exemestane Resistant: B - Late Trials
|
exemestane Resistant: B - Late Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: B - Late Trials
|
fulvestrant Sensitive: B - Late Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Resistant: B - Late Trials
|
exemestane Resistant: B - Late Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
RAD1901 Sensitive: B - Late Trials
|
RAD1901 Sensitive: B - Late Trials
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: B - Late Trials
|
fulvestrant Sensitive: B - Late Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
Aromatase inhibitor + palbociclib Resistant: B - Late Trials
|
Aromatase inhibitor + palbociclib Resistant: B - Late Trials
|
ER mutation
|
Breast Cancer
|
ER mutation
|
Breast Cancer
|
fulvestrant Sensitive: C2 – Inclusion Criteria
|
fulvestrant Sensitive: C2 – Inclusion Criteria
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
GDC-9545 Sensitive: C2 – Inclusion Criteria
|
GDC-9545 Sensitive: C2 – Inclusion Criteria
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
palbociclib + PF-05212384 Sensitive: C3 – Early Trials
|
palbociclib + PF-05212384 Sensitive: C3 – Early Trials
|
ER mutation
|
Breast Cancer
|
ER mutation
|
Breast Cancer
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
enobosarm Sensitive: C3 – Early Trials
|
enobosarm Sensitive: C3 – Early Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
SAR439859 Sensitive: C3 – Early Trials
|
SAR439859 Sensitive: C3 – Early Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Resistant: C3 – Early Trials
|
alpelisib Resistant: C3 – Early Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
G1T48 Sensitive: C4 – Case Studies
|
G1T48 Sensitive: C4 – Case Studies
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
RAD1901 Sensitive: D – Preclinical
|
RAD1901 Sensitive: D – Preclinical
|